Trial Profile

A Phase II Study of STEMVAC Vaccine Therapy for Patients With Hormone Receptor Positive Metastatic Breast Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 18F-fluoroestradiol (Primary) ; Capecitabine (Primary) ; Cyclin-dependent kinase 4 inhibitors (Primary) ; Cyclin-dependent kinase 6 inhibitors (Primary) ; EP 101-EpiThany (Primary) ; Hormones (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Adverse reactions; Pharmacodynamics

Most Recent Events

30 Oct 2025 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Nov 2025 to 24 Nov 2025.
02 Oct 2025 Planned initiation date changed from 1 Jan 2026 to 1 Nov 2025.
02 Oct 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com